Verastem, Inc. (VSTM) EPS Estimated At $-0.40

October 13, 2018 - By Marie Mckinney

Investors sentiment increased to 2.07 in 2018 Q2. Its up 0.91, from 1.16 in 2018Q1. It improved, as 15 investors sold Verastem, Inc. shares while 15 reduced holdings. 36 funds opened positions while 26 raised stakes. 30.86 million shares or 129.37% more from 13.46 million shares in 2018Q1 were reported.
Qs Invsts Limited Liability Company has invested 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Citigroup owns 7,238 shares. Jpmorgan Chase owns 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 174,573 shares. Savings Bank Of America Corp De has invested 0% in Verastem, Inc. (NASDAQ:VSTM). 11,670 are held by Bluecrest Mgmt. Grp One Trading L P accumulated 0% or 47,551 shares. Amer Intll Grp Inc holds 0% or 34,433 shares in its portfolio. 269,626 were accumulated by Bogle Inv Lp De. Tiaa Cref Inv Management Limited Co invested in 0% or 117,424 shares. Creative Planning has 58,550 shares for 0% of their portfolio. 267,593 are held by Howland Capital Mgmt Lc. Alliancebernstein Ltd Partnership holds 87,600 shares. Panagora Asset Mngmt owns 184,616 shares or 0.01% of their US portfolio. Invesco Limited has invested 0% in Verastem, Inc. (NASDAQ:VSTM). Pnc Financial reported 0% stake.

Analysts expect Verastem, Inc. (NASDAQ:VSTM) to report $-0.40 EPS on November, 6.They anticipate $0.21 EPS change or 34.43 % from last quarter’s $-0.61 EPS. After having $-0.30 EPS previously, Verastem, Inc.’s analysts see 33.33 % EPS growth. The stock decreased 9.31% or $0.58 during the last trading session, reaching $5.65. About 9.88M shares traded or 233.94% up from the average. Verastem, Inc. (NASDAQ:VSTM) has risen 69.08% since October 14, 2017 and is uptrending. It has outperformed by 53.46% the S&P500.

Verastem, Inc. (NASDAQ:VSTM) Ratings Coverage

Among 3 analysts covering Verastem (NASDAQ:VSTM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Verastem had 4 analyst reports since May 2, 2018 according to SRatingsIntel. The company was maintained on Thursday, May 10 by FBR Capital. The rating was maintained by FBR Capital with “Buy” on Friday, June 8.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $415.80 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

More notable recent Verastem, Inc. (NASDAQ:VSTM) news were published by: Seekingalpha.com which released: “Verastem: Post FDA Approval Investment Thesis” on September 27, 2018, also Fool.com with their article: “Here’s Why Verastem Dropped Precipitously Today” published on October 12, 2018, Seekingalpha.com published: “Verastem Oncology prices registered direct offering of $150M convertible notes” on October 12, 2018. More interesting news about Verastem, Inc. (NASDAQ:VSTM) were released by: Streetinsider.com and their article: “Verastem (VSTM) Announces NCCN Adds its COPIKTRA Capsules to Clinical Practice Guidelines in Oncology” published on October 08, 2018 as well as Businesswire.com‘s news article titled: “Verastem Oncology Announces Pricing of Registered Direct Offering of $150 Million of Convertible Notes” with publication date: October 11, 2018.

Verastem, Inc. (NASDAQ:VSTM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>